(Q47972160)

7 February 2018

title

Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes (English)

1 reference

7 February 2018

0 references

A Panahloo

1

1 reference

7 February 2018

V Mohamed-Ali

2

1 reference

7 February 2018

C Andrés

3

1 reference

7 February 2018

A E Denver

4

1 reference

7 February 2018

J S Yudkin

5

1 reference

7 February 2018

publication date

1 June 1998

1 reference

7 February 2018

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

Metabolism

1 reference

7 February 2018

volume

47

1 reference

7 February 2018

issue

6

1 reference

7 February 2018

page(s)

637-643

1 reference

7 February 2018

Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990023-3

Circulating proinsulin-like molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990023-3

The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990023-3

Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990023-3

Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990023-3

Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990023-3

Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990023-3

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990023-3

Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990023-3

Glucose, insulin and somatostatin infusion for the determination of insulin sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990023-3

The two-period cross-over clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990023-3

Treatment of NIDDM with insulin agonists or substitutes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990023-3

Rise of plasma t-PA fibrinolytic activity in a group of maturity onset diabetic patients shifted from a first generation (tolbutamide) to a second generation sulphonylurea (gliclazide).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990023-3

Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990023-3

Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990023-3

Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990023-3

Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990023-3

Relationship of hepatic and peripheral insulin resistance with plasminogen activator inhibitor-1 in Pima Indians.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990023-3

Insulin and PAI-1 levels during oral glucose tolerance test in patients with coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990023-3

Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990023-3

Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990023-3

10.1016/S0026-0495(98)90023-3

7 January 2021

Identifiers

DOI

1 reference

7 February 2018

release_auakuozj2vg6npxcqhqkxiilp4

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/auakuozj2vg6npxcqhqkxiilp4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

7 February 2018